STAR Ph3 study of mavorixafor in sbjcts with neutropenic disorders w/ recurrent serious infections
Phase III Clinical Trial
A Phase 3 randomized double-blind placebo-controlled multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections (X4P-001-110)
Participating Locations